Cargando…
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial
This is a summary of a research article reporting Part A of the CheckMate 914 study (NCT03138512; EudraCT 2016-004502-34). Following surgery to remove renal cell carcinoma (RCC), people with a high risk of the cancer returning received nivolumab plus ipilimumab (adjuvant therapy) or placebo to see i...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10517884/ https://www.ncbi.nlm.nih.gov/pubmed/37659025 http://dx.doi.org/10.1007/s11523-023-00987-1 |
| _version_ | 1785109392724590592 |
|---|---|
| author | Motzer, Robert J. Russo, Paul Grünwald, Viktor Tomita, Yoshihiko Zurawski, Bogdan Parikh, Omi Buti, Sebastiano Barthélémy, Philippe Goh, Jeffrey C. Ye, Dingwei Lingua, Alejo Lattouf, Jean-Baptiste Albigès, Laurence George, Saby Shuch, Brian Sosman, Jeffrey Staehler, Michael Vázquez Estévez, Sergio Simsek, Burcin Spiridigliozzi, Julia Chudnovsky, Aleksander Bex, Axel |
| author_facet | Motzer, Robert J. Russo, Paul Grünwald, Viktor Tomita, Yoshihiko Zurawski, Bogdan Parikh, Omi Buti, Sebastiano Barthélémy, Philippe Goh, Jeffrey C. Ye, Dingwei Lingua, Alejo Lattouf, Jean-Baptiste Albigès, Laurence George, Saby Shuch, Brian Sosman, Jeffrey Staehler, Michael Vázquez Estévez, Sergio Simsek, Burcin Spiridigliozzi, Julia Chudnovsky, Aleksander Bex, Axel |
| author_sort | Motzer, Robert J. |
| collection | PubMed |
| description | This is a summary of a research article reporting Part A of the CheckMate 914 study (NCT03138512; EudraCT 2016-004502-34). Following surgery to remove renal cell carcinoma (RCC), people with a high risk of the cancer returning received nivolumab plus ipilimumab (adjuvant therapy) or placebo to see if this risk was reduced. The results of this study showed that the risk of RCC returning or death was not changed with adjuvant nivolumab plus ipilimumab treatment compared with placebo. In addition, people treated with nivolumab plus ipilimumab had more side effects compared with people treated with placebo (89% versus 57%). |
| format | Online Article Text |
| id | pubmed-10517884 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-105178842023-09-25 Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial Motzer, Robert J. Russo, Paul Grünwald, Viktor Tomita, Yoshihiko Zurawski, Bogdan Parikh, Omi Buti, Sebastiano Barthélémy, Philippe Goh, Jeffrey C. Ye, Dingwei Lingua, Alejo Lattouf, Jean-Baptiste Albigès, Laurence George, Saby Shuch, Brian Sosman, Jeffrey Staehler, Michael Vázquez Estévez, Sergio Simsek, Burcin Spiridigliozzi, Julia Chudnovsky, Aleksander Bex, Axel Target Oncol Summary of Research This is a summary of a research article reporting Part A of the CheckMate 914 study (NCT03138512; EudraCT 2016-004502-34). Following surgery to remove renal cell carcinoma (RCC), people with a high risk of the cancer returning received nivolumab plus ipilimumab (adjuvant therapy) or placebo to see if this risk was reduced. The results of this study showed that the risk of RCC returning or death was not changed with adjuvant nivolumab plus ipilimumab treatment compared with placebo. In addition, people treated with nivolumab plus ipilimumab had more side effects compared with people treated with placebo (89% versus 57%). Springer International Publishing 2023-09-02 2023 /pmc/articles/PMC10517884/ /pubmed/37659025 http://dx.doi.org/10.1007/s11523-023-00987-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Summary of Research Motzer, Robert J. Russo, Paul Grünwald, Viktor Tomita, Yoshihiko Zurawski, Bogdan Parikh, Omi Buti, Sebastiano Barthélémy, Philippe Goh, Jeffrey C. Ye, Dingwei Lingua, Alejo Lattouf, Jean-Baptiste Albigès, Laurence George, Saby Shuch, Brian Sosman, Jeffrey Staehler, Michael Vázquez Estévez, Sergio Simsek, Burcin Spiridigliozzi, Julia Chudnovsky, Aleksander Bex, Axel Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial |
| title | Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial |
| title_full | Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial |
| title_fullStr | Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial |
| title_full_unstemmed | Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial |
| title_short | Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial |
| title_sort | summary of research: adjuvant nivolumab plus ipilimumab versus placebo for localized renal cell carcinoma after nephrectomy (checkmate 914): a double-blind, randomized, phase 3 trial |
| topic | Summary of Research |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10517884/ https://www.ncbi.nlm.nih.gov/pubmed/37659025 http://dx.doi.org/10.1007/s11523-023-00987-1 |
| work_keys_str_mv | AT motzerrobertj summaryofresearchadjuvantnivolumabplusipilimumabversusplaceboforlocalizedrenalcellcarcinomaafternephrectomycheckmate914adoubleblindrandomizedphase3trial AT russopaul summaryofresearchadjuvantnivolumabplusipilimumabversusplaceboforlocalizedrenalcellcarcinomaafternephrectomycheckmate914adoubleblindrandomizedphase3trial AT grunwaldviktor summaryofresearchadjuvantnivolumabplusipilimumabversusplaceboforlocalizedrenalcellcarcinomaafternephrectomycheckmate914adoubleblindrandomizedphase3trial AT tomitayoshihiko summaryofresearchadjuvantnivolumabplusipilimumabversusplaceboforlocalizedrenalcellcarcinomaafternephrectomycheckmate914adoubleblindrandomizedphase3trial AT zurawskibogdan summaryofresearchadjuvantnivolumabplusipilimumabversusplaceboforlocalizedrenalcellcarcinomaafternephrectomycheckmate914adoubleblindrandomizedphase3trial AT parikhomi summaryofresearchadjuvantnivolumabplusipilimumabversusplaceboforlocalizedrenalcellcarcinomaafternephrectomycheckmate914adoubleblindrandomizedphase3trial AT butisebastiano summaryofresearchadjuvantnivolumabplusipilimumabversusplaceboforlocalizedrenalcellcarcinomaafternephrectomycheckmate914adoubleblindrandomizedphase3trial AT barthelemyphilippe summaryofresearchadjuvantnivolumabplusipilimumabversusplaceboforlocalizedrenalcellcarcinomaafternephrectomycheckmate914adoubleblindrandomizedphase3trial AT gohjeffreyc summaryofresearchadjuvantnivolumabplusipilimumabversusplaceboforlocalizedrenalcellcarcinomaafternephrectomycheckmate914adoubleblindrandomizedphase3trial AT yedingwei summaryofresearchadjuvantnivolumabplusipilimumabversusplaceboforlocalizedrenalcellcarcinomaafternephrectomycheckmate914adoubleblindrandomizedphase3trial AT linguaalejo summaryofresearchadjuvantnivolumabplusipilimumabversusplaceboforlocalizedrenalcellcarcinomaafternephrectomycheckmate914adoubleblindrandomizedphase3trial AT lattoufjeanbaptiste summaryofresearchadjuvantnivolumabplusipilimumabversusplaceboforlocalizedrenalcellcarcinomaafternephrectomycheckmate914adoubleblindrandomizedphase3trial AT albigeslaurence summaryofresearchadjuvantnivolumabplusipilimumabversusplaceboforlocalizedrenalcellcarcinomaafternephrectomycheckmate914adoubleblindrandomizedphase3trial AT georgesaby summaryofresearchadjuvantnivolumabplusipilimumabversusplaceboforlocalizedrenalcellcarcinomaafternephrectomycheckmate914adoubleblindrandomizedphase3trial AT shuchbrian summaryofresearchadjuvantnivolumabplusipilimumabversusplaceboforlocalizedrenalcellcarcinomaafternephrectomycheckmate914adoubleblindrandomizedphase3trial AT sosmanjeffrey summaryofresearchadjuvantnivolumabplusipilimumabversusplaceboforlocalizedrenalcellcarcinomaafternephrectomycheckmate914adoubleblindrandomizedphase3trial AT staehlermichael summaryofresearchadjuvantnivolumabplusipilimumabversusplaceboforlocalizedrenalcellcarcinomaafternephrectomycheckmate914adoubleblindrandomizedphase3trial AT vazquezestevezsergio summaryofresearchadjuvantnivolumabplusipilimumabversusplaceboforlocalizedrenalcellcarcinomaafternephrectomycheckmate914adoubleblindrandomizedphase3trial AT simsekburcin summaryofresearchadjuvantnivolumabplusipilimumabversusplaceboforlocalizedrenalcellcarcinomaafternephrectomycheckmate914adoubleblindrandomizedphase3trial AT spiridigliozzijulia summaryofresearchadjuvantnivolumabplusipilimumabversusplaceboforlocalizedrenalcellcarcinomaafternephrectomycheckmate914adoubleblindrandomizedphase3trial AT chudnovskyaleksander summaryofresearchadjuvantnivolumabplusipilimumabversusplaceboforlocalizedrenalcellcarcinomaafternephrectomycheckmate914adoubleblindrandomizedphase3trial AT bexaxel summaryofresearchadjuvantnivolumabplusipilimumabversusplaceboforlocalizedrenalcellcarcinomaafternephrectomycheckmate914adoubleblindrandomizedphase3trial |